X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MNKD-101 (clofazimine) possesses antimicrobial and anti-inflammatory properties. It is active against both slowly growing and rapidly growing mycobacteria and most Gram-positive bacteria in vitro. It is currently being developemnt for pulmonary nontuberculous mycobacteria.
Lead Product(s): Clofazimine
Therapeutic Area: Infections and Infectious Diseases Product Name: MNKD-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
Afrezza (technosphere insulin) is a USFDA approved insulin receptor agonist which is being evaluated for the treatment of type 1 or type 2 diabetes in pediatric patients.
Lead Product(s): Technosphere Insulin,Degludec
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Under the terms agreement, Sagard Healthcare will receive royalty payments on net sales of Tyvaso DPI (treprostinil) inhalation powder indicated for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Tyvaso DPI
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sagard Healthcare
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 02, 2024
Details:
Afrezza (human Insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist, which is investigated in combination with insulin degludec for the treatment of type 1 diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: Phase IVProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
Afrezza (human insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist and works as starts lowering blood sugars in ~12 minutes for adults living with type 1 or type 2 diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: Phase IVProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
MNKD-101 (clofazimine) possesses antimicrobial and anti-inflammatory properties. It is active against both slowly growing and rapidly growing mycobacteria and most Gram-positive bacteria in vitro. It is currently being developemnt for pulmonary nontuberculous mycobacteria.
Lead Product(s): Clofazimine
Therapeutic Area: Infections and Infectious Diseases Product Name: MNKD-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
During the MAD portion of the study, 16 adults were enrolled in one of two cohorts (n = 8 per cohort) that received a daily inhaled dose of 30 mg or 90 mg MNKD-101 (clofazimine) for a seven-day period.
Lead Product(s): Clofazimine
Therapeutic Area: Infections and Infectious Diseases Product Name: MNKD-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
MannKind will also publish an abstract on “Augmenting Clinical Trial Data within Silico Evidence to Evaluate Initial Conversion Dose Changes for Technosphere® Insulin (Afrezza).” The abstract will be published in category 12-E Clinical Therapeutics/New Technology – Insulins.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
Studies with TYVASO (Treprostinil) establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Tyvaso DPI
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
The proof-of-concept study demonstrated that a simplified 2x dose of Technosphere® Insulin (TI) provided significant reductions in post-prandial glucose excursions (PPGE) versus current label dosage guidelines, with no new safety concerns.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
